1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Delayed London Stock Exchange  -  05/25 11:35:24 am EDT
1775.00 GBX   -0.39%
05/24TRANSCRIPT : GSK plc Presents at UBS Global Healthcare Conference, May-24-2022 09:15 AM
CI
05/24European executives' confidence plunges on Ukraine crisis - survey
RE
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline Opts to Extend Partnership with 23andMe

01/18/2022 | 07:58am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
23ANDME HOLDING CO. 3.21% 2.89 Delayed Quote.-56.61%
GLAXOSMITHKLINE PLC -0.39% 1775 Delayed Quote.10.48%
ON SEMICONDUCTOR CORPORATION 3.19% 56.24 Delayed Quote.-17.20%
All news about GLAXOSMITHKLINE PLC
05/24TRANSCRIPT : GSK plc Presents at UBS Global Healthcare Conference, May-24-2022 09:15 AM
CI
05/24European executives' confidence plunges on Ukraine crisis - survey
RE
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
MD
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
FA
05/18S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
MT
05/17FTSE 100 lags European peers on strong pound
RE
05/17GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
05/16GlaxoSmithKline Adopts Shortened GSK Name
MT
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2022 36 527 M 45 865 M 45 865 M
Net income 2022 5 289 M 6 641 M 6 641 M
Net Debt 2022 17 655 M 22 168 M 22 168 M
P/E ratio 2022 16,7x
Yield 2022 2,96%
Capitalization 89 836 M 113 B 113 B
EV / Sales 2022 2,94x
EV / Sales 2023 2,79x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 775,00 GBX
Average target price 1 865,77 GBX
Spread / Average Target 5,11%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC10.48%112 914
JOHNSON & JOHNSON5.00%477 336
PFIZER, INC.-9.04%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY11.15%275 413
ABBVIE INC.12.23%263 494